|
|
|||||||||
Clinical Investigation |
1 Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; 2 Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; 3 Department of Oral and Maxillofacial Surgery, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; 4 Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; and 5 Department of Otorhinolaryngology, Head and Neck Surgery, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
Correspondence: For correspondence or reprints contact: Esther G.C. Troost, MD, Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. E-mail: e.troost{at}rther.umcn.nl
Repopulation of clonogenic tumor cells is inversely correlated with radiation treatment outcome in head and neck squamous cell carcinomas. A functional imaging tool to assess the proliferative activity of tumors could improve patient selection for treatment modifications and could be used for evaluation of early treatment response. The PET tracer 3'-deoxy-3'-18F-fluorothymidine (18F-FLT) can image tumor cell proliferation before and during radiotherapy, and it may provide biologic tumor information useful in radiotherapy planning. In the present study, the value of 18F-FLT PET in determining the lymph node status in squamous cell carcinoma of the head and neck was assessed, with pathology as the gold standard. Methods: Ten patients with newly diagnosed stage IIIV squamous cell carcinoma of the head and neck underwent 18F-FLT PET before surgical tumor resection with lymph node dissection. Emission 18F-FLT PET and CT images of the head and neck were recorded and fused, and standardized uptake values (SUVs) were calculated. From all 18 18F-FLT PET-positive lymph node levels and from 8 18F-FLT PET-negative controls, paraffin-embedded lymph node sections were stained and analyzed for the endogenous proliferation marker Ki-67 and for the preoperatively administered proliferation marker iododeoxyuridine. The sensitivity, specificity, positive predictive value, and negative predictive value were calculated for 18F-FLT PET. Results: Primary tumor sites were oral cavity (n = 7), larynx (n = 2), and maxillary sinus (n = 1). Nine of the 10 patients examined had 18F-FLT PET-positive lymph nodes (SUVmean: median, 1.2; range, 0.82.9), but only 3 of these patients had histologically proven metastases. All metastatic lymph nodes showed Ki-67 and iododeoxyuridine staining in tumor cells. In the remaining 7 patients, there was abundant Ki-67 and iododeoxyuridine staining of B-lymphocytes in germinal centers in PET-positive lymph nodes, explaining the high rate of false-positive findings. The sensitivity, specificity, positive predictive value, and negative predictive value of 18F-FLT PET were 100%, 16.7%, 37.5%, and 100%, respectively. Conclusion: In head and neck cancer patients, 18F-FLT PET showed uptake in metastatic as well as in nonmetastatic reactive lymph nodes, the latter due to reactive B-lymphocyte proliferation. Because of the low specificity, 18F-FLT PET is not suitable for assessment of pretreatment lymph node status. This observation may also negatively influence the utility of 18F-FLT PET for early treatment response evaluation of small metastatic nodes.
Key Words: 18F-FLT PET/CT staging head and neck cancer
COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.
Related articles in JNM:
This article has been cited by other articles:
![]() |
E. G.C. Troost, D. A.X. Schinagl, J. Bussink, O. C. Boerman, A. J. van der Kogel, W. J.G. Oyen, and J. H.A.M. Kaanders Innovations in Radiotherapy Planning of Head and Neck Cancers: Role of PET J. Nucl. Med., January 1, 2010; 51(1): 66 - 76. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Menda, L. L. Boles Ponto, K. J. Dornfeld, T. J. Tewson, G. L. Watkins, M. K. Schultz, J. J. Sunderland, M. M. Graham, and J. M. Buatti Kinetic Analysis of 3'-Deoxy-3'-18F-Fluorothymidine (18F-FLT) in Head and Neck Cancer Patients Before and Early After Initiation of Chemoradiation Therapy J. Nucl. Med., July 1, 2009; 50(7): 1028 - 1035. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Brepoels, S. Stroobants, G. Verhoef, T. De Groot, L. Mortelmans, and C. De Wolf-Peeters 18F-FDG and 18F-FLT Uptake Early After Cyclophosphamide and mTOR Inhibition in an Experimental Lymphoma Model J. Nucl. Med., July 1, 2009; 50(7): 1102 - 1109. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Schoder, M. Fury, N. Lee, and D. Kraus PET Monitoring of Therapy Response in Head and Neck Squamous Cell Carcinoma J. Nucl. Med., May 1, 2009; 50(Suppl_1): 74S - 88S. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. G.C. Troost, J. Bussink, W. J.G. Oyen, and J. H.A.M. Kaanders 18F-FDG and 18F-FLT Do Not Discriminate Between Reactive and Metastatic Lymph Nodes in Oral Cancer J. Nucl. Med., March 1, 2009; 50(3): 490 - 491. [Full Text] [PDF] |
||||
![]() |
K. Herrmann, F. Eckel, S. Schmidt, K. Scheidhauer, B. J. Krause, J. Kleeff, T. Schuster, H.-J. Wester, H. Friess, R. M. Schmid, et al. In Vivo Characterization of Proliferation for Discriminating Cancer from Pancreatic Pseudotumors J. Nucl. Med., September 1, 2008; 49(9): 1437 - 1444. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Bading and A. F. Shields Imaging of Cell Proliferation: Status and Prospects J. Nucl. Med., June 1, 2008; 49(Suppl_2): 64S - 80S. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. A. Kyzas, E. Evangelou, D. Denaxa-Kyza, and J. P. A. Ioannidis 18F-Fluorodeoxyglucose Positron Emission Tomography to Evaluate Cervical Node Metastases in Patients With Head and Neck Squamous Cell Carcinoma: A Meta-analysis J Natl Cancer Inst, May 21, 2008; 100(10): 712 - 720. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |